Neuro-Oncology Reviews
Volume
28 Number 24
31 August 2026
Home > Publications > Neuro-Oncology Reviews > Volume 28, Year 2026 > Number 24, 31 August
Alomari O, Alomari T, Güney B, Eyvazova H, Benamara TS,
Alomari S, Bingöl M, Odabas H.
Systemic
and local dysregulation of the complement system in glioma: a
comprehensive systematic review.
Clin
Transl Oncol. 2026 Aug 21. doi:
10.1007/s12094-026-04552-w. PMID:
42627589˰ ˍ
Chen L, Zou Z.
CAR-T Cell Therapy for
Glioblastoma: Obstacles and Advances.
Crit
Rev Oncol Hematol. 2026 Aug 21;227:105556. doi:
10.1016/j.critrevonc.2026.105556. PMID:
42628610. ˍ
Qiu Q, Zhang T, Song P, Deng H, Liu Y, Bu J, Zhang M.
Decoding
the spatiotemporal dynamics of T cell immune landscapes in
glioblastoma: remodeling precision combination therapies.
Biochim
Biophys Acta Rev Cancer. 2026 Aug 21;1881(5):189691.
doi:
10.1016/j.bbcan.2026.189691. PMID:
42628660. ˍ
Liu Y, Guo C, Wang X, Huang K, Huang S, Cao J, Deng M, Guan T,
Zhang Y, Tian S, Zheng Z.
The
Brain-tumor axis: Tumor pathogenesis and therapeutic strategies
from a cancer neuroscience perspective.
Cancer
Treat Res Commun. 2026 Aug 22;49:101384. doi:
10.1016/j.ctarc.2026.101384. PMID:
42632358. ˍ
Nageeb G, Ha JH, Liu J, Sjoholm MA, Lim M.
Immunotherapy
for Glioma: A compartmental framework for resistance and rational
combination design.
Neurotherapeutics.
2026 Aug 22;23(6):e01035. doi:
10.1016/j.neurot.2026.e01035. PMID:
42632152. ˍ
Nassor M, Chaudhry S, Zahin F, Roy S, Odei KPK, Nkrumah-Boateng
PA, Wireko AA.
Ferroptosis as an
immunometabolic checkpoint in brain tumours: spatial
vulnerabilities and therapeutic opportunities.
Mol
Brain. 2026 Aug 24;19(1):63. doi:
10.1186/s13041-026-01344-9. PMID:
42638114. ˍ
Raut S, Bhatt LK.
Targeting
glioblastoma epigenetics: mechanisms, microenvironmental
interplay, and therapeutic potential.
Neuroscience.
2026 Aug 25;615:102-119. doi:
10.1016/j.neuroscience.2026.08.039. PMID:
42641911˰ ˍ
Chojak R, Turunen JR, Drewes NB, Koutah L, Fares J, Chen RX, Du R,
Faisal UH, Kazi HA, Kelley C, Miska J, Heimberger AB, Ahmed AU,
Lesniak MS.
The intersection of
chemokine signaling with the hallmarks of cancer in glioblastoma.
J
Neurooncol. 2026 Aug 26;179(2):55. doi:
10.1007/s11060-026-05768-0. PMID:
42645633. ˍ
Freeman H, Rawson C, Baloi D, Karsy M, Pahlevani M.
Brain-Tropic
Metastasis: Mechanistic Checkpoints Governing Cerebral
Colonization.
Oncology.
2026 Aug 26:1. doi:
10.1159/ocl/aebag007. PMID:
42647421. ˍ
Anvarian A, Nazari FSM, Karimi Jashni A.
Armoring
CAR-T Cells Against Exhaustion: Engineering Strategies for
Glioblastoma.
J
Immunother. 2026 Aug 27. doi:
10.1097/CJI.0000000000000617. PMID:
42657603˰ ˍ
Mamala M, Marczuk K, Rembiałkowska N.
Molecular
mechanisms of exosome-mediated drug resistance in central nervous
system tumours.
Crit
Rev Oncol Hematol. 2026 Aug 30;227:105571. doi:
10.1016/j.critrevonc.2026.105571. PMID:
42669321. ˍ
Jabri A, Mhannayeh A, Taftafa B, Alsharif M, Sibai D, Alsharif R,
Abbad T, Elsalti A, Ahmed Z, Salma J, Khan MI, Yaqinuddin
A.
Recent advances in immunotherapy for
gliomas: overcoming barriers and advancing precision strategies.
Front
Immunol. 2026 Jan 8;16:1690464. doi:
10.3389/fimmu.2025.1690464. PMID:
41583467. ˍ
Schonfeld E, Sjoholm A, Ha J, Liu J, Nageeb G, Annagiri S, Kim L,
Choi J, Lim M.
Next-generation
immunotherapy biologics for glioblastoma.
Front
Immunol. 2026 Mar 18;17:1775093. doi:
10.3389/fimmu.2026.1775093. PMID:
41929511. ˍ
Hill CM, Nwagwu CD, Odukoya AO, Hsueh B, Wang AZ, Dunn GP.
Tumor
infiltrating lymphocytes in glioblastoma: immunobiology and
translational implications.
NPJ
Precis Oncol. 2026 Jul 13;10(1):274. doi:
10.1038/s41698-026-01330-3. PMID:
42437767. ˍ
Figueira K, Pigott LE.
Outcomes of
target therapies for pediatric BRAF V600-mutant low-grade gliomas:
A systematic review and meta-analysis.
Neurooncol
Adv. 2026 Jul 27;8(1):vdag192. doi:
10.1093/noajnl/vdag192. PMID:
42633479. ˍ
Walton CM, Strickland BA.
Complement-Targeted
Therapies in Glioblastoma: A Systematic Review.
Biomedicines.
2026 Jul 29;14(8):1702. doi:
10.3390/biomedicines14081702. PMID:
42652085. ˍ
Sarrazin E, Valable S, Pérès EA, Colloc'h N, Emery
E, Lesueur P, Leclerc A, Bernaudin M, Aury-Landas J.
Glioblastoma
and resistance to radiotherapy: role of cancer stem cells
subpopulations, hypoxia and therapeutic strategies.
Cancer
Treat Rev. 2026 Aug 1;149:103198. doi:
10.1016/j.ctrv.2026.103198. PMID:
42659714. ˍ
Chao CC, Shen HE, Zhang BB, Chao TC, Wang CW, Wu CC.
Challenges
and Opportunities of γδ T Cell-Based Immunotherapy for
Glioblastoma.
Biomedicines.
2026 Aug 6;14(8):1770. doi:
10.3390/biomedicines14081770. PMID:
42652153. ˍ
Elemam NM, Sweillam JH, El-Sherif Y, Youssef YA, Ismail HM, Assal
RA, Youness RA.
Long non-coding RNAs
in glioblastoma: from molecular drivers to therapeutic targets.
Front
Immunol. 2026 Aug 7;17:1887815. doi:
10.3389/fimmu.2026.1887815. PMID:
42630738. ˍ
Russo F, Ricci M, Dadgar H, Travascio L, De Feo MS, Brunotti G,
Usmani S, Arabi H, Anwar FM, Khalaf AN, Filippi L, Cimini
A.
PSMA-Targeted Theranostics in
Glioblastoma Multiforme: Current Evidence and Future Perspectives.
Int
J Mol Sci. 2026 Aug 8;27(16):7112. doi:
10.3390/ijms27167112. PMID:
42653114. ˍ
Aydın HA, Keskin E, Kalaycı M.
Reprogramming
the immunosuppressive microenvironment in glioblastoma: the
microglia-MDSC-Treg axis and translational therapeutic strategies.
Front
Oncol. 2026 Aug 10;16:1782775. doi:
10.3389/fonc.2026.1782775. PMID:
42639384. ˍ
Prajapati S, Yadav S.
Engineered
Exosomes as Next-generation Nanotherapeutics for Glioma: Crossing
the Blood-brain Barrier Toward Precision Medicine.
Curr
Neurovasc Res. 2026 Aug 10. doi:
10.2174/0115672026464128260804075922. PMID:
42634375. ˍ
Tianqing Z, Yuan G, Qianyi Y, Yanchu L.
Review
of glioblastoma and systemic comorbidities.
Front
Oncol. 2026 Aug 10;16:1882982. doi:
10.3389/fonc.2026.1882982. PMID:
42639360. ˍ
Lichtor T, O-Sullivan I, Tang B.
Editorial:
Immunotherapeutic advances in brain tumours.
Front
Immunol. 2026 Aug 12;17:1949875. doi:
10.3389/fimmu.2026.1949875. PMID:
42657017. ˍ
Eddy EM, Patton T, Barrow AD, Corbett AJ.
Unconventional
guardians of the brain: MAIT cells as emerging players in
glioblastoma immunity.
Front
Immunol. 2026 Aug 13;17:1896626. doi:
10.3389/fimmu.2026.1896626. PMID:
42662577. ˍ
Cantor E, Qutob H, Ayers J, Donnville B, Nieves C, Cruz-Flores V,
Stapleton S, Patel NJ.
Report from the
National Pediatric Cancer Foundation - infantile glioma and other
non-embryonal central nervous system tumors: evolving molecular
advances and current treatment landscape.
Front
Oncol. 2026 Aug 14;16:1874371. doi:
10.3389/fonc.2026.1874371. PMID:
42666540. ˍ
Popescu SO, Popa DC, Alexandru O, Dricu A.
Obstacles
and Trials in Treating Primary Brain Tumors.
Int
J Mol Sci. 2026 Aug 18;27(16):7390. doi:
10.3390/ijms27167390. PMID:
42653393. ˍ
Urbanic-Purkart T.
IDH-Mutant Diffuse
Glioma: From Metabolic Origins to Targeted Therapy.
J
Clin Med. 2026 Aug 18;15(16):6387. doi:
10.3390/jcm15166387. PMID:
42652791. ˍ
Engelhardt B, Platten M.
Brain
barriers at the crossroads of glioma immune surveillance and
immunotherapy response.
Nat
Rev Cancer. 2026 Aug 20. doi:
10.1038/s41568-026-00960-w. PMID:
42624896˰ ˍ
Kuczyński N, Larysz D, Uchman-Rzeżnik D, Irianto G,
Pilewski D.
The Invasive Margin of
Glioblastoma as a Molecular Ecosystem: Spatial Heterogeneity,
Tumor-Host Interactions, and Therapeutic Opportunities.
Int
J Mol Sci. 2026 Aug 20;27(16):7449. doi:
10.3390/ijms27167449. PMID:
42653450. ˍ